1.2 OMIM# of the disease 180200.
1.3 Name of the analysed genes or DNA/chromosome segments RB1.
1.4 OMIM# of the gene(s) 180200.
Mutational spectrum
Germline mutations: point mutations, deletions, insertions. Somatic mutations (tumour only): point mutations, deletions, insertions, epigenetic silencing (somatic), chromosomal rearrangements (somatic loss of heterozygosity).
Analytical methods
Chromosome analysis, FISH, sequence analysis, MLPA/quantitative multiplex PCR, testing for loss of heterozygosity, methylation analysis.
Addendum:
(1) RB1 testing is proposed for all patients with a retinoblastoma diagnosis irrespective of the nature at the time of presentation (unilateral, bilateral, sporadic, familial).
(2) In patients with retinoblastoma who also present with dysmorphic features and/or developmental delay chromosomal analysis, FISH or array CGH analysis is performed first.
(3) If tumour tissue is available, the aim is to determine the mutations that inactivate the two RB1 alleles (either two somatic mutations or one somatic mutation and a germline mutation). Analytical methods for the study of DNA from tumours include sequence analysis, MLPA/quantitative multiplex PCR, testing for loss of heterozygosity and methylation analysis.
Following identification of the mutations that inactivate the two RB1 alleles, constitutional DNA (for example, extracted from blood) is tested for the presence of these mutations.
(4) If no tumour tissue is available, the aim is to determine a mutation that inactivates one of the two RB1 alleles. Analytical methods for the study of DNA from blood include sequence analysis and MLPA/quantitative multiplex PCR.
(5) Mutational mosaicism is not uncommon in patients with isolated (sporadic) retinoblastoma. Methods for mutation detection in DNA from blood must be sensitive enough to permit the detection of mutant alleles present in only a fraction of the DNA analysed.
Analytical validation
In some cases (for example, single-exon deletions detected by MLPA), the results of semiquantitative methods should be confirmed by an independent technique (long-range PCR -sequencing, RNA analysis, segregation of genetic variation).
1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence) Prevalence of retinoblastoma: 1/15 000 to 1/20 000 (40% bilateral, 60% unilateral).
Hereditary retinoblastoma susceptibility present in 50% of patients (all familial cases, almost all sporadic bilateral cases, and 13% of unilateral cases).
1.9 If applicable, prevalence in the ethnic group of the investigated person Not applicable.
Diagnostic setting
Comment: Not applicable.
TEST CHARACTERISTICS

Yes.
No. Use of molecular genetic testing for early identification of asymptomatic at-risk children in a family improves diagnostic certainty and reduces the need for costly screening procedures in those at-risk family members who have not inherited the disease-causing mutation. 4 If the test result is negative (please describe): If the test is negative, surveillance is not required.
Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been carried out (please describe)?
Eye examination every 3-4 weeks until the age of 1 year and then less frequently until the age of 5 years is recommended; young and/or uncooperative children usually require examination under anaesthesia. To detect second non-ocular tumours in individuals with retinoblastoma, physicians and parents should promptly evaluate complaints of bone pain or lumps because of the high risk of sarcomas; however, no specific screening protocols exist. Limitation exposures to DNA-damaging agents (radiotherapy, tobacco and UV light) may reduce the excess cancer risks in hereditary retinoblastoma survivors. Testing of relatives at risk: Use of molecular genetic testing for early identification of asymptomatic at-risk children in a family improves diagnostic certainty and reduces the need for costly screening procedures in those at-risk family members who have not inherited the disease-causing mutation.
3.3 Genetic risk assessment in family members of a diseased person (To be answered if in 1.10 'C' was marked) 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or for his/her relatives? (Please describe).
